| Assessment Status | Rapid Review Complete |
| HTA ID | 22034 |
| Drug | Pasireotide LAR |
| Brand | Signifor® LAR |
| Indication | For the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue. |
| Assessment Process | |
| Rapid review commissioned | 13/05/2022 |
| Rapid review completed | 16/06/2022 |
| Rapid review outcome | for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement – July 2022.
